These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8913487)

  • 1. Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals.
    Been-Tiktak AM; Williams I; Vrehen HM; Richens J; Aldam D; van Loon AM; Loveday C; Boucher CA; Ward P; Weller IV; Borleffs JC
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2664-8. PubMed ID: 8913487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team.
    Reichman RC; Morse GD; Demeter LM; Resnick L; Bassiakos Y; Fischl M; Para M; Powderly W; Leedom J; Greisberger C
    J Infect Dis; 1995 Feb; 171(2):297-304. PubMed ID: 7531207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.
    Demeter LM; Meehan PM; Morse G; Fischl MA; Para M; Powderly W; Leedom J; Holden-Wiltse J; Greisberger C; Wood K; Timpone J; Wathen LK; Nevin T; Resnick L; Batts DH; Reichman RC
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2):135-44. PubMed ID: 9768622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients.
    Been-Tiktak AM; Vrehen HM; Schneider MM; van der Feltz M; Branger T; Ward P; Cox SR; Harry JD; Borleffs JC
    Antimicrob Agents Chemother; 1995 Mar; 39(3):602-7. PubMed ID: 7793859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.
    Morse GD; Fischl MA; Shelton MJ; Borin MT; Driver MR; DeRemer M; Lee K; Wajszczuk CP
    Antimicrob Agents Chemother; 1996 Mar; 40(3):767-71. PubMed ID: 8851608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials.
    Eron JJ
    AIDS; 1996 Dec; 10 Suppl 5():S11-9. PubMed ID: 9030391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.
    Morse GD; Reichman RC; Fischl MA; Para M; Leedom J; Powderly W; Demeter LM; Resnick L; Bassiakos Y; Timpone J; Cox S; Batts D
    Antiviral Res; 2000 Jan; 45(1):47-58. PubMed ID: 10774589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
    Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
    Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.
    Suleiman J; Zingman BS; Diaz RS; Madruga JV; DeJesus E; Slim J; Mak C; Lee E; McCarthy MC; Dunkle LM; Walmsley S
    J Infect Dis; 2010 Feb; 201(4):590-9. PubMed ID: 20064072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
    J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.
    Spruance SL; Pavia AT; Mellors JW; Murphy R; Gathe J; Stool E; Jemsek JG; Dellamonica P; Cross A; Dunkle L
    Ann Intern Med; 1997 Mar; 126(5):355-63. PubMed ID: 9054279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
    Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Ait-Khaled M; Purdon S
    AIDS; 2000 May; 14(7):781-9. PubMed ID: 10839585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.
    Kahn J; Lagakos S; Wulfsohn M; Cherng D; Miller M; Cherrington J; Hardy D; Beall G; Cooper R; Murphy R; Basgoz N; Ng E; Deeks S; Winslow D; Toole JJ; Coakley D
    JAMA; 1999 Dec 22-29; 282(24):2305-12. PubMed ID: 10612317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
    Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
    AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
    Campbell TB; Young RK; Eron JJ; D'Aquila RT; Tarpley WG; Kuritzkes DR
    J Infect Dis; 1993 Aug; 168(2):318-26. PubMed ID: 7687641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.
    Deeks SG; Collier A; Lalezari J; Pavia A; Rodrigue D; Drew WL; Toole J; Jaffe HS; Mulato AS; Lamy PD; Li W; Cherrington JM; Hellmann N; Kahn J
    J Infect Dis; 1997 Dec; 176(6):1517-23. PubMed ID: 9395363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study.
    Erb P; Battegay M; Zimmerli W; Rickenbach M; Egger M
    Arch Intern Med; 2000 Apr; 160(8):1134-40. PubMed ID: 10789606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    Ann Intern Med; 2002 Sep; 137(5 Pt 2):381-433. PubMed ID: 12617573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.